Magenta Therapeutics and Heidelberg Pharma Sign Exclusive Multi-Target Research Agreement for the Development of Antibody Drug Conjugates

Kala Pharmaceuticals Appoints Gregory Perry to Board of Directors and as Audit Committee Chair

Sage Therapeutics to Present at Cowen & Co. 38th Annual Health Care Conference

CytomX to Present at Upcoming Investor Conferences

Jounce Therapeutics to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Thursday, March 8, 2018

MyoKardia to Report Fourth Quarter and Full Year 2017 Financial Results on Thursday, March 8, 2018

Editas Medicine Supports Rare Disease Day® and Joins Global Movement to Raise Important Awareness for Rare Diseases

Fulcrum Therapeutics to Present at the 11th Annual Future of Genomic Medicine Conference

Voyager Therapeutics to Host Fourth Quarter and Full Year 2017 Financial Results and Corporate Highlights Conference Call

Magenta Therapeutics Presents Clinical and Preclinical Data at ASBMT Conference, Including New Preclinical Results on Microglial Engraftment with MGTA-456 Expanded Cord Blood Stem Cell Product

Voyager Therapeutics to Present at Cowen Health Care Conference

CytomX Therapeutics to Announce Full-Year 2017 Financial Results and Host Operational Update Webcast Conference Call

Sage Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Pipeline Update

bluebird bio Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational Progress

Magenta Therapeutics Hires John Davis, MD, MPH, as Chief Medical Officer

Blueprint Medicines Reports Fourth Quarter and Full Year 2017 Financial Results

Voyager Therapeutics and AbbVie Announce Global Strategic Collaboration to Develop Potential New Treatments for Alzheimer’s Disease and Other Tau-Related Neurodegenerative Diseases

Editas Medicine Names Jessica Hopfield, Ph.D., to Board of Directors

FDA Accepts New Drug Application and Grants Priority Review for Ivosidenib in Relapsed or Refractory AML with an IDH1 Mutation

Agios Reports Fourth Quarter and Full Year 2017 Financial Results

bluebird bio Appoints Alison Finger as Chief Commercial Officer

Blueprint Medicines to Report Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 21, 2018

MyoKardia to Present at the RBC Capital Markets’ 2018 Healthcare Conference

MyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in Dilated Cardiomyopathy Patients

Sage Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on Thursday, February 22, 2018

Foundation Medicine Announces Timing for Fourth Quarter and Year-End 2017 Financial Results and Conference Call

Sage Therapeutics to Present at Leerink Partners 7th Annual Global Healthcare Conference

Constellation Pharmaceuticals Announces Upcoming Presentations of Lead EZH2 and BET Clinical Programs

Editas Medicine to Participate in Upcoming Investor Conferences

Eleven Biotherapeutics to Present at 2018 BIO CEO & Investor Conference

Zafgen to Present at the Leerink Partners 7th Annual Global Healthcare Conference

GBT Announces Participation at the Leerink Partners 7th Annual Global Healthcare Conference

Sage Therapeutics Receives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder

Voyager Therapeutics to Present at Leerink Partners Annual Global Healthcare Conference

bluebird bio to Present at LEERINK Partners Global Healthcare Conference

Sage Therapeutics Announces Positive Results from Placebo-Controlled Trial in a Model of Insomnia Demonstrating Activity on Sleep Parameters and Supporting Development of SAGE-217 as Potential Treatment for Sleep Disorders

Voyager Therapeutics Announces CEO Succession Plan for 2018

Foundation Medicine and European Organisation for Research and Treatment of Cancer (EORTC) Announce Collaboration to Advance Precision Medicine Using Comprehensive Genomic Profiling to Facilitate Clinical Trial Enrollment

Eleven Biotherapeutics Appoints Richard Fitzgerald as Chief Financial Officer

Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

Voyager Therapeutics Announces FDA Clearance of Investigational New Drug Application for VY-AADC for Advanced Parkinson’s Disease

MyoKardia Announces Appointment of Cynthia Ladd as General Counsel

Agios Announces Pricing of $475 Million Public Offering of Common Stock

Agios Announces Proposed Offering of Common Stock

Constellation Pharmaceuticals Announces Initiation of Phase 1b/2 Study of CPI-1205

Foundation Medicine and Pfizer Announce Broad Partnership to Develop Companion Diagnostics for Pfizer's Oncology Portfolio

GBT Receives FDA Breakthrough Therapy Designation for Voxelotor for Treatment of Sickle Cell Disease (SCD)

Editas Medicine Reports on Recent Progress and Announces “EM22†Five-year Goals at J.P. Morgan Healthcare Conference

Foundation Medicine Reports Preliminary 2017 Results

Sage Therapeutics to Provide Pipeline Update at J.P. Morgan Healthcare Conference and Outline Key 2018 Initiatives to Support Planned Evolution to a Fully-Integrated Commercial Biopharmaceutical Company